You are here

COMMENTARY

The real lesson from Eli Lilly's Alzheimer's drug trial failure

Digging through unsuccessful drug experiments to find justification for moving forward with medicines is a recipe for failing again.
Monday, November 28, 2016 - 05:50

New York

THE most anticipated pharma news of 2016 lived down to expectations.   Following in the footsteps of nearly every other company that has sought to treat Alzheimer's disease, Eli Lilly announced last Wednesday that its Alzheimer's drug solanuzemab (sola) failed a huge Phase 3

sentifi.com

Market voices on:

Nespresso
Pair your daily business read with the perfect cup of espresso.

Subscribe to The Business Times today to receive your very own Nespresso Inissia coffee machine worth $188.

Find out more at btsub.sg/btdeal

Powered by GET.comGetCom